Cartalax is supplied as a catalogued research material in 20 mg.
Cartalax is described in registry and literature records as the tripeptide Ala-Glu-Asp, abbreviated AED. It should not be represented as an AEDG tetrapeptide, and a vendor-circulated CAS number should be omitted until independently verified [1,2].
Chemical properties and registry information
| Property | Value |
|---|---|
| Name and synonyms | ADGE, Ala-Asp-Gly-Glu, Карталакс |
| Material category | Bioregulator Peptide |
| Sequence | H-ADGE-OH |
| Molecular formula | C14H22N4O9 |
| Average molecular mass | 390.35 g/mol |
| PubChem CID | CID 135458181 |
| Structural features | Linear tetrapeptide |
| Appearance | White to off-white lyophilised powder |
| Solubility | Readily soluble in bacteriostatic or sterile water. |
| Physical form | Catalogue vial; exact salt/counter-ion and excipients are batch-specific and must be verified in the CoA and SDS. |
Registry values apply only to the specific molecular entity, sequence, termini and material form. Batch records take precedence over family-level literature identifiers.
A Khavinson peptide bioregulator studied for its effects on cartilage and the musculoskeletal system.
Research background and published evidence
Published research
Published Cartalax/AED work is concentrated in cell, tissue and animal models concerning peptide-regulated gene-expression and cartilage-related research [2,3].
Current scientific understanding
The located evidence is predominantly preclinical, and robust published human clinical evidence was not identified. These studies do not establish safety, efficacy or equivalence for this catalogue batch.
AED and AEDG are different sequences and must not share molecular or registry identifiers.
Technical comparison
| Aspect | This catalogue material | Comparator |
|---|---|---|
| Identity | Cartalax/AED tripeptide, subject to batch confirmation | AEDG tetrapeptide |
| Structural distinction | Three-residue Ala-Glu-Asp sequence | Four-residue Ala-Glu-Asp-Gly sequence |
| Analytical implication | Confirm the three-residue sequence, termini, intact mass and salt form | The added Gly gives a distinct sequence and molecular mass |
Quality and testing
Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.
Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.
Laboratory handling and storage
Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.
Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment and waste disposal should follow the applicable SDS and the institution’s approved procedures.
Regulatory and legal status
| Research-use notice | This material is supplied exclusively for laboratory research by qualified professionals and is not intended for human or veterinary use. Purchasers are responsible for compliance with applicable local requirements. |
Sources and references
- [1] PubChem. Alanyl-glutamyl-aspartic acid, CID 87815447.
- [2] U.S. National Library of Medicine MeSH. Alanyl-glutamyl-aspartic acid/Cartalax record.
- [3] Khavinson et al. Review of short peptide regulation and Cartalax/AED research (2023).
Frequently Asked Questions
Do the CAS number and PubChem CID apply to every batch form?
Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.
What does an analytical purity result mean?
It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.
How should the material be stored and handled?
Follow the exact label, batch CoA and SDS together with the institution’s risk assessment. Use only storage and stability information linked to the exact material form and batch.
